JPWO2022226261A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022226261A5 JPWO2022226261A5 JP2023565207A JP2023565207A JPWO2022226261A5 JP WO2022226261 A5 JPWO2022226261 A5 JP WO2022226261A5 JP 2023565207 A JP2023565207 A JP 2023565207A JP 2023565207 A JP2023565207 A JP 2023565207A JP WO2022226261 A5 JPWO2022226261 A5 JP WO2022226261A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- inhibitor
- therapeutic agent
- tumor therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178922P | 2021-04-23 | 2021-04-23 | |
| US63/178,922 | 2021-04-23 | ||
| PCT/US2022/025875 WO2022226261A1 (en) | 2021-04-23 | 2022-04-22 | Treatment of cancer with a raf inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024516972A JP2024516972A (ja) | 2024-04-18 |
| JPWO2022226261A5 true JPWO2022226261A5 (https=) | 2025-04-25 |
| JP2024516972A5 JP2024516972A5 (https=) | 2025-04-25 |
Family
ID=83722622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565207A Pending JP2024516972A (ja) | 2021-04-23 | 2022-04-22 | Ｒａｆ阻害薬による癌の処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11918587B2 (https=) |
| EP (1) | EP4326256A4 (https=) |
| JP (1) | JP2024516972A (https=) |
| KR (1) | KR20240000534A (https=) |
| CN (1) | CN117561057A (https=) |
| AU (1) | AU2022261117A1 (https=) |
| BR (1) | BR112023021913A2 (https=) |
| CA (1) | CA3216104A1 (https=) |
| IL (1) | IL307908A (https=) |
| MX (1) | MX2023012515A (https=) |
| TW (1) | TW202308645A (https=) |
| WO (1) | WO2022226261A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022007612A2 (pt) | 2019-10-24 | 2022-09-20 | Kinnate Biopharma Inc | Inibidores de raf quinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| CN117561057A (zh) | 2021-04-23 | 2024-02-13 | 金耐特生物制药公司 | 用raf抑制剂治疗癌症 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| AU2024322235A1 (en) * | 2023-08-09 | 2026-02-26 | Pierre Fabre Medicament | Treatment of cancer with a raf inhibitor |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025145207A1 (en) * | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CN1087725C (zh) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| WO2006071940A2 (en) | 2004-12-23 | 2006-07-06 | Deciphera Pharmaceuticals, Llc | Enzyme modulators and treatments |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| AR067354A1 (es) | 2007-06-29 | 2009-10-07 | Sunesis Pharmaceuticals Inc | Compuestos utiles como inhibidores de la raf quinasa |
| CA2714700C (en) | 2008-02-22 | 2013-07-30 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| WO2010078408A1 (en) | 2008-12-30 | 2010-07-08 | Biogen Idec Ma Inc. | Heteroaryl compounds useful as raf kinase inhibitors |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| DK3366293T3 (da) | 2012-06-07 | 2020-06-15 | Deciphera Pharmaceuticals Llc | Dihydronaphthyridiner og relaterede forbindelser, der er nyttige som kinashæmmere til behandling af proliferative sygdomme |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| US10167279B2 (en) | 2014-09-12 | 2019-01-01 | Novartis Ag | Compounds and compositions as RAF kinase inhibitors |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| WO2020168172A1 (en) | 2019-02-15 | 2020-08-20 | Zamboni Chem Solutions Inc. | Conjugate compounds for the degradation of raf |
| JP2022525885A (ja) | 2019-03-22 | 2022-05-20 | キネート バイオファーマ インク． | Ｒａｆキナーゼの阻害剤 |
| US10927111B2 (en) * | 2019-05-03 | 2021-02-23 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| BR112022007612A2 (pt) | 2019-10-24 | 2022-09-20 | Kinnate Biopharma Inc | Inibidores de raf quinases |
| US11407737B2 (en) * | 2020-09-18 | 2022-08-09 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| CN117529313A (zh) | 2021-04-23 | 2024-02-06 | 金耐特生物制药公司 | 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯烷-1-甲酰胺及其盐 |
| CN117561057A (zh) * | 2021-04-23 | 2024-02-13 | 金耐特生物制药公司 | 用raf抑制剂治疗癌症 |
-
2022
- 2022-04-22 CN CN202280045318.4A patent/CN117561057A/zh active Pending
- 2022-04-22 AU AU2022261117A patent/AU2022261117A1/en active Pending
- 2022-04-22 JP JP2023565207A patent/JP2024516972A/ja active Pending
- 2022-04-22 MX MX2023012515A patent/MX2023012515A/es unknown
- 2022-04-22 WO PCT/US2022/025875 patent/WO2022226261A1/en not_active Ceased
- 2022-04-22 KR KR1020237039412A patent/KR20240000534A/ko active Pending
- 2022-04-22 BR BR112023021913A patent/BR112023021913A2/pt unknown
- 2022-04-22 CA CA3216104A patent/CA3216104A1/en active Pending
- 2022-04-22 TW TW111115522A patent/TW202308645A/zh unknown
- 2022-04-22 IL IL307908A patent/IL307908A/en unknown
- 2022-04-22 EP EP22792545.0A patent/EP4326256A4/en active Pending
-
2023
- 2023-04-06 US US18/296,726 patent/US11918587B2/en active Active
-
2024
- 2024-01-26 US US18/424,274 patent/US12569496B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022226261A5 (https=) | ||
| US20210000951A1 (en) | Combination therapies | |
| Atreya et al. | Systemic therapy for metastatic colorectal cancer: from current standards to future molecular targeted approaches | |
| JP2020105162A5 (https=) | ||
| US20120294867A1 (en) | Method for egfr directed combination treatment of cancer | |
| CA2715353A1 (en) | Use of picoplatin and cetuximab to treat colorectal cancer | |
| JP2020533298A (ja) | Ｈｅｒ誘発性薬剤耐性がんの治療又は予防のための化合物、組成物及び方法 | |
| EP2981169B1 (en) | Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate | |
| JP2019525948A (ja) | 薬学的組み合わせ | |
| Barbie et al. | Phase 1B study of momelotinib combined with trametinib in metastatic, kirsten rat sarcoma viral oncogene homolog-mutated non–small-cell lung cancer after platinum-based chemotherapy treatment failure | |
| CN112043702A (zh) | 用于联合治疗结直肠癌的喹啉类化合物 | |
| CN113811298B (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| CN111973747A (zh) | 用于联合治疗卵巢癌的喹啉衍生物 | |
| CN112121048A (zh) | 用于联合治疗食管癌的喹啉类化合物 | |
| AU2020278733B2 (en) | Quinoline derivatives for treatment of head and neck cancer | |
| EP4512401A1 (en) | Pharmaceutical for treating or preventing cancer | |
| Pentheroudakis et al. | Incorporation of targeted agents in the management of patients with advanced gastric cancer | |
| Grothey | Optimizing systemic therapy selection in metastatic colorectal cancer | |
| HK40072142A (en) | Quinoline derivative used for combination treatment of small cell lung cancer | |
| CN117083283A (zh) | 用于癌症治疗的联合疗法 | |
| Harris | Inhibitors of Vascular Endothelial Growth Factor Receptor | |
| US20160367553A1 (en) | Methods and Compositions for Treating Cancers having Acquired Resitance to prior Chemotherapeutic and Targeted Drugs Using Carboxyamidotriazole Orotate | |
| Jimeno et al. | Membrane receptor and antiangiogenic targeted therapies in the treatment of cancer | |
| Noel et al. | Management of Metastatic Colorectal 62 Cancer | |
| Johnson et al. | MAPK Pathway Overview |